Ardelyx (ARDX) is back in focus after presenting new long term data on XPHOZAH at the National Kidney Foundation’s Spring Clinical Meetings, reinforcing the drug’s safety profile in dialysis patients with hyperphosphatemia.

The latest XPHOZAH data comes after a busy few weeks that included first quarter results and reiterated 2026 revenue guidance. Yet the stock has eased in the very short term with a 1-day share price return of 2.87% and a 7-day share price return of 7.12%, despite a 1-year total shareholder return of 92.07% that points to strong longer term momentum.

If this kind of clinical update catches your attention, it can be useful to see what else is moving across the sector and check out 34 healthcare AI stocks

With Ardelyx shares easing in the short term, trading around $6.78 with a market cap near $1.7b and an analyst price target more than double the latest close, the key question is whether this represents a mispricing or whether the market is already factoring in future growth.

Most Popular Narrative: 58.5% Undervalued

With Ardelyx last closing at $6.78 against a narrative fair value of $16.33, the gap between current pricing and expectations is hard to ignore.

Product life cycle extension opportunities, such as potential new indications, pediatric use, or further patient segmentation for tenapanor-based therapies, offer further avenues for revenue diversification and durability, positively impacting both revenue trajectory and long-term earnings resilience.

Curious what kind of revenue curve and profit margin shift would need to play out to support that fair value, and how long that runway really is.

Result: Fair Value of $16.33 (UNDERVALUED)

However, investors still need to weigh key risks, such as reliance on tenapanor based products and ongoing Medicare reimbursement uncertainty around XPHOZAH, that could derail this thesis.

Next Steps

Given the mixed signals around valuation and risk, it can be useful to act promptly on your own research and decide where you stand. Start by reviewing the 4 key rewards

Looking for more investment ideas?

If you stop here, you risk missing other stocks that could fit your goals just as well as Ardelyx, or even suit you better.

• Spot potential underpriced opportunities early by running your filters through 49 high quality undervalued stocks.
• Strengthen your focus on financial resilience with the solid balance sheet and fundamentals stocks screener (44 results).
• Uncover lesser known prospects that still screen well on fundamentals using the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.